You are here

Enhertu

AI tool could help doctors ID breast cancers vulnerable to Enhertu

BioPharma Dive

Thu, 05/22/25 - 09:21 pm

artificial intelligence

New data could move Enhertu into early breast cancer

Pharmaphorum

Wed, 05/7/25 - 11:15 am

clinical trials

early breast cancer

AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer

Fierce Pharma

Mon, 04/21/25 - 11:12 am

clinical trials

Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial

Clinical Trials Arena

Tue, 03/4/25 - 09:48 am

clinical trials

gastroesophageal adenocarcinoma

Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer

BioPharma Dive

Tue, 01/28/25 - 10:40 am

HER2-low breast cancer

England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo

Fierce Pharma

Tue, 11/19/24 - 07:14 pm

AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again

Fierce Biotech

Tue, 11/12/24 - 08:44 pm

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Pharmaphorum

Fri, 11/8/24 - 11:37 am

Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns

Medical Marketing and Media

Sun, 09/22/24 - 09:46 pm

metastatic breast cancer

ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases

Clinical Trials Arena

Tue, 09/17/24 - 11:20 am

metastatic breast cancer

clinical trials

EU starts review of Enhertu in HER2-ultra-low breast cancer

Pharmaphorum

Mon, 08/19/24 - 09:56 am

After tense standoff, AstraZeneca and Daiichi's Enhertu turned away by NICE on pricing grounds

Fierce Pharma

Mon, 07/29/24 - 10:51 am

HER2-low breast cancer

Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms

BioSpace

Mon, 07/1/24 - 11:14 am

ASCO: AstraZeneca, Daiichi's Enhertu looks to make history again in HER2-ultralow breast cancer

Fierce Pharma

Sun, 06/2/24 - 02:46 pm

The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel

Pharma Voice

Fri, 05/10/24 - 11:12 am

AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial

Clinical Trials Arena

Mon, 04/29/24 - 11:12 am

HER2-low breast cancer

FDA grants accelerated approval to Enhertu for metastatic HER2-positive cancers

Investing.com

Sun, 04/7/24 - 04:45 pm

Surprise Enhertu rejection follows NICE process change

Pharmaphorum

Tue, 03/5/24 - 11:35 am

HER2-low breast cancer

Daiichi Sankyo again dials up Enhertu sales forecast, advances 2nd AstraZeneca-partnered ADC

Fierce Pharma

Wed, 01/31/24 - 10:27 pm

Pages